Teva, Active Biotech: Laquinimod reduces relapses, disease progression in MS patients

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

The drug makers said the drug, laquinimod, reduced annualized relapse rates by 23% and disability progression by 36% in the phase-3 “Allegro” study. The drug also reduced brain tissue loss by 33%. In addition, the companies said the drug was safe and well-tolerated, without suppression of the immune system. Laquinimod is a once-daily, orally administered treatment. Teva also makes the injected MS drug Copaxone (glatiramer acetate).

“The Allegro study results are exciting, as they suggest that oral laquinimod is a novel therapeutic option that safely slows MS disease activity and progression,” principal study investigator and medical professor at the University Vite Salute in San Raffaele, Italy, Giancarlo Comi, said.

Login or Register to post a comment.